Inflammatory Myeloradiculitis Secondary to Pembrolizumab: A Case Report and Literature Review

Table 2

Treatment and outcomes of reported cases of myelitis-related adverse events secondary to PD-L1 inhibitor therapy.

Author	Treatment	Outcome
Carausu et al. [20]	Oral steroid 60 mg/day tapered over 2 months	Complete resolution, Pembrolizumab reinitiated without recurrence of myelitis
Chang et al. [21]	Dexamethasone 8 mg BD, bevacizumab 2 doses, 1000 mg daily methylprednisolone for 5 days, plasmapheresis, cyclophosphamide 100 mg/m3, and infliximab	Dramatic improvement post infliximab, however succumbed to malignancy soon after
Durães et al. [23]	Corticosteroid therapy for 5 days and plasma exchange for 7 sessions	Almost complete symptomatic recovery with residual mild sensory complaints
Narumi et al. [24]	Pulse steroid therapy, plasmapheresis	Minimal improvement
Poretto et al. [25]	High-dose steroid	Mild clinical and radiological improvement
Wilson et al. [27]	Intravenous methylprednisolone followed by oral prednisolone taper, intravenous immunoglobulins, and plasma exchange	Near complete remission, mild residual hypertonia